Total: $626.134M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@


Acacia Research
Corp.
(ACTG)

Private placement of units

2.4U

$5.28

Acacia raised $5.28M in a private placement of 2.4M units (5/21)

Advanced Viral Research
Corp.
(OTC BB: ADVR) and
warrants

Private placement of convertible debentures, common stock

10.3S and W for 6.2S

$1.83

Advanced Viral raised $1M through the placement of convertible debentures, due April 28, 2008, with Cornell Capital Partners; it also raised $826,000 with the placement of 10.325M shares and warrants to purchase 6.195M shares (5/16)

Ariad Pharmaceuticals
Inc.
(ARIA)

Private placement of common stock

4S

$10

Ariad raised $10M with the placement of 4M shares with The Riverview Group LLC and Merlin Biomed Group (5/19)

AVI BioPharma
Inc.
(AVII)

Private placement of common stock

3S

$15

AVI BioPharma raised $15M in the private placement with several unnamed institutional investors; Rodman & Renshaw Inc. acted as the placement agent in the transaction (5/5)

Biokeys
Pharmaceuticals
Inc.
(OTC BB:BKYS)

Private placement of common stock and warrants

5S and W for 1.5S

$2

Biokeys raised $2M in a private placement of 5M shares and warrants to purchase an aggregate of just more than 1.5M shares (5/28)

Biomira Inc. (Canada; BIOM; TSE:BRA)

Private placement of common stock and warrants

3.25S and 0.548W

$3.7

Biomira raised US$3.7M in the placement of 3.25M shares and up to 548,148 warrants (5/9)

Bioniche Life
Sciences Inc.
(Canada; TSE:BNC)

Private placement of debentures

N/A

C$13.5 (US$9.8)

Bioniche raised US$9.8M with the placement of royalty-enhanced debentures to the Business Development Bank of Canada and two other Canadian financial institutions; Harris Partners Ltd. was the lead agent, and Octagon Capital Corp. co-led the financing (5/27)

Biopure Corp.
(BPUR)

Private placement of common stock

N/A

$7.3

Biopure raised $7.3M with the private placement of common stock to several investors; BNY Capital Markets Inc. was the placement agent (5/6)

Celgene Corp.
(CELG)

Private placement of convertible notes

N/A

$400

Celgene privately placed $325M in convertible notes; the unnamed purchaser also exercised an option to purchase an additional $75M in notes (5/30)

CV Technologies Inc. (Canada; CVTX)

Private placement of units

25.5U

C$2.55 (US$1.85)

CV Technologies raised US$1.85M with a private placement of up to 25.5M units, each consisting of one common share and one common share purchase warrant; Brubuck Inc. purchased 20M units (5/14)

CytrRx Corp.
(CYTR)

Private placement of common stock

2.9S

$5.44

CytRx raised $5.44M with the placement of 2.9M common shares (5/30)

EntreMed Inc.
(ENMD)

Private placement of common stock

3S

$9

EntreMed raised $9M after selling 3M common shares to a group of undisclosed institutional investors (5/20)

Genaera Corp.
(GENR)

Private placement of convertible preferred stock

0.005S

$5

Genaera raised $5M in a sale of 5,000 shares of convertible preferred stock to Biotechnology Value Fund LP and associated entities and to Ziff Asset Management LP (5/28)

Genelabs
Technologies
Inc.
(GNLB)

Private placement of common stock and warrants

8.1S and W for 2.43S

$8.1

Genelabs raised $8.1M in the placement with institutional and accredited investors; SG Cowen Securities Corp. acted as the transaction's placement agent (5/5)

Generex
Biotechnology
Corp.
(Canada; GNBT)

Private placement of common stock

2.8S

$3.2

Generex issued about 2.8M shares to accredited institutional investors, raising $3.2M (5/29)

Guilford
Pharmaceuticals

Inc.
(GLFD)

Term loan

N/A

--

Guilford entered an $18.8M term loan with Wachovia Bank (5/7)

Helix BioMedix
Inc.
(OTC BB:
HXBM)

Private placement of stock and warrants

2.3S

$2.3

Helix raised $2.3M, adding to the $1.5M already raised in January (5/7)

Hemispherx
Biopharma Inc.
(AMEX:HEB)

Private placement of senior convertible debentures and warrants

0.74W

$5.5

Hemispherx raised $5.5M in the private placement that was conducted in March, but not previously reported in Financial Watch; Cardinal Securities LLC acted as placement agent; investors were Ramius Capital Group and Angelo, Gordon and Co. (3/12)

Immunomedics
Inc.
(IMMU)

Bond financing

N/A

$6.4

Immunomedics completed a $6.4M bond financing with the New Jersey Economic Development Authority; the proceeds are to be repaid over a five-year period (5/28)

IntraBiotics Pharmaceuticals
Inc.
(IBPI)

Private placement of convertible preferred stock and warrants

1.8S

$3.5

IntraBiotics raised $3.5M, issuing preferred stock that will convert to about 1.8M common shares; also it issued warrants to purchase about 920,000 common shares (5/2)

Isolagen Inc. (AMEX:ILE)

Private placement of convertible preferred stock

0.16S

$4.4

Isolagen raised $4.4M with a private offering of 155,750 shares of Series B convertible preferred stock at $28 apiece; Fordham Financial Management Inc. managed the offering (5/30)

PharmaNetics Inc. (PHAR)

Private placement of convertible preferred stock

N/A

$9.6

PharmaNetics raised $9.6M in a private placement of preferred stock convertible into common stock at $6 per share, and warrants to purchase an additional 510,932 common shares for $7.12; the financing was led by Camden Partners (5/1)

Repligen Corp. (RGEN)

Private placement of common stock

2.5S

$12.5

Repligen raised $12.5M through a private placement of 2.5M shares at $5 each to The Riverview Group; Rodman & Renshaw Inc. served as placement agent (5/2)

Resverlogix Corp. (Canada; CDNX:RVX)

Private placement of common stock

N/A

C$3
(US$2.15)

Resverlogix raised US$2.15M in a private financing through a reverse-takeover share exchange with Apsley Management Group Inc. (5/8)

Seattle Genetics
Inc.
(SGEN)

Private placement of convertible preferred stock and warrants

1.6S and W for 2S

$40

Seattle Genetics raised $40M selling 1.6M shares of stock convertible into 16M common shares, and warrants to buy 2M shares of stock; the placement was led by JP Morgan Partners LLC and Baker Brothers Investments; other investors were Delphi Ventures and BA Venture Partners (5/13)

Spectrum Pharmaceuticals
Inc.
(SPPI)

Private placement of convertible preferred stock

N/A

$4.4

Spectrum raised $4.4M through the sale of the stock to institutional investors, including SCO Capital Partners, SDS Merchant Fund, Xmark Funds and ProMed Partners LP (5/8)

StemCells Inc. (STEM)

Private placement of common stock

4S

$6.5

StemCells raised $6.5M through the sale of 4M common shares to The Riverview Group LLC (5/13)

Transition Therapeutics Inc. (Canada; CDNX:TTH)

Private placement of common stock

6.2S

C$0.664 (US$0.484)

Transition raised US$483,740 in a financing (5/26)

VaxGen Inc.
(VXGN)

Private placement of common stock

1.74S

$5

VaxGen raised $5M after selling 1.74M shares to an unnamed institutional investor (5/20)

V.I. Technologies
Inc.
(VITX)

Private placement of common stock

19.8S

$18.4

V.I. Technologies raised $18.4M in a shareholder rights offering; the financing included participation by several existing venture and institutional investors, along with directors and officers of the company (5/27)

Vivus Inc.
(VVUS)

Private placement of common stock

4.4S

$17.5

Vivus raised $17.5M following a private placement of 4.4M shares; investors were Zesiger Capital Group LLC, SAC Capital Associates LLC, Royal Bank of Canada, Baystar Capital II LP and Special Situations Funds; C.E. Unterberg, Towbin acted as the exclusive placement agent (5/28)


Notes:

This chart does not include real estate or manufacturing plant financings.

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.